Increased Expression of miR-146a in Children With Allergic Rhinitis After Allergen-Specific Immunotherapy.
10.4168/aair.2016.8.2.132
- Author:
Xi LUO
1
;
Haiyu HONG
;
Jun TANG
;
Xingmei WU
;
Zhibin LIN
;
Renqiang MA
;
Yunping FAN
;
Geng XU
;
Dabo LIU
;
Huabin LI
Author Information
1. Department of Otolaryngology, Affiliated Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. daboliu@126.com, allergyli@163.com
- Publication Type:Original Article
- Keywords:
Allergic rhinitis;
immunotherapy;
miR-146a;
Foxp3;
TRAF6;
IL-10
- MeSH:
Biomarkers;
Blotting, Western;
Cell Differentiation;
Child*;
Enzyme-Linked Immunosorbent Assay;
Flow Cytometry;
Humans;
Immunotherapy*;
Interleukin-10;
Interleukin-5;
MicroRNAs;
Polymerase Chain Reaction;
Reverse Transcription;
Rhinitis*;
RNA, Messenger;
Sublingual Immunotherapy;
T-Lymphocytes;
TNF Receptor-Associated Factor 6
- From:Allergy, Asthma & Immunology Research
2016;8(2):132-140
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: MicroRNAs (miRs) were recently recognized to be important for immune cell differentiation and immune regulation. However, whether miRs were involved in allergen-specific immunotherapy (SIT) remains largely unknown. This study sought to examine changes in miR-146a and T regulatory cells in children with persistent allergic rhinitis (AR) after 3 months of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). METHODS: Twenty-four HDM-sensitized children with persistent AR were enrolled and treated with SCIT (n=13) or SLIT (n=11) for 3 months. Relative miR-146a and Foxp3 mRNA expression, the TRAF6 protein level, and the ratio of post-treatment to baseline IL-10+CD4+ T cells between the SCIT and SLIT groups were examined in the peripheral blood mononuclear cells (PBMCs) of AR patients using quantitative reverse transcription polymerase chain reaction (qRT-PCR), flow cytometry, and Western blot analysis, respectively. Serum levels of IL-5 and IL-10 were determined using ELISA. RESULTS: After 3 months of SIT, both the TNSS and INSS scores were significantly decreased compared to the baseline value (P<0.01). The relative expression of miR-146a and Foxp3 mRNA was significantly increased after both SCIT and SLIT (P<0.01). The ratio of post-treatment to baseline IL-10+CD4+ T cells and the serum IL-10 level were significantly increased in both the SCIT and SLIT groups (P<0.01), whereas the TRAF6 protein level and serum IL-5 level were significantly decreased (P<0.01). No significant differences in these biomarkers were observed between the SCIT and SLIT groups. CONCLUSIONS: Our findings suggest that miR-146a and its related biomarkers may be comparably modulated after both SCIT and SLIT, highlighting miR-146a as a potential therapeutic target for the improved management of AR.
